Chiome Bioscience Inc. (TSE:4583) entered into a contract to acquire 52.9% stake in LivTech Inc. from KSP No. 2 Limited Partnership Fund and KSP No. 3 Limited Partnership Fund managed by KSP Inc., Medical & Biological Laboratories Co., Ltd. (JASDAQ:4557), JAFCO Incubation No. 2 Venture Capital Investment Limited Partnership, Yume Fund No. 3, a fund of Yokohama Capital Co. Ltd., Life Science Venture Fund II managed by ReqMed Venture Capital and MBL Venture Capital Co., Ltd., Koji Nakamura and Reiko Nakayama for ¥87.8 million on December 16, 2013. Chiome Bioscience will acquire 225 B preferred shares of LivTech at a price of ¥390,000 million per share.

LivTech Inc. reported net assets of ¥0.12 million, total assets of ¥0.23 million, sales of ¥0.13 million, operating loss of ¥0.07 million and net loss of ¥0.07 million for period ended December 2012. The transaction is expected to be completed on December 25, 2013.

Chiome Bioscience Inc. (TSE:4583) completed the acquisition of 52.9% stake in LivTech Inc. from KSP No. 2 Limited Partnership Fund and KSP No. 3 Limited Partnership Fund managed by KSP Inc., Medical & Biological Laboratories Co., Ltd. (JASDAQ:4557), JAFCO Incubation No. 2 Venture Capital Investment Limited Partnership, Yume Fund No. 3, a fund of Yokohama Capital Co. Ltd., Life Science Venture Fund II managed by ReqMed Venture Capital and MBL Venture Capital Co., Ltd., Koji Nakamura and Reiko Nakayama on December 25, 2013.